Results 81 to 90 of about 6,658 (202)

Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge

Cells
Poly (ADP-ribose) polymerase inhibitors (PARPis) show cytotoxicity in homologous recombination deficiency (HRD) seen in BRCA-mutant ovarian cancer (OvCa). Despite initial responses, resistance often develops.
Chi-Ting Shih, Tzu-Ting Huang, Jayakumar R. Nair, Kristen R. Ibanez, Jung-Min Lee   +4 more
doaj   +1 more source

Rucaparib and Niraparib in Advanced Ovarian Cancer

Journal of the Advanced Practitioner in Oncology, 2019
Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration-approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy in previously treated ovarian cancers, with niraparib demonstrating activity in both BRCA-mutated and BRCA wild-type tumors ...
openaire   +3 more sources

Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer

, 2017
Objective: To review the pharmacology, safety, efficacy, and the role of rucaparib in the treatment of relapsed, advanced ovarian cancer. Summary: A total of 2 phase I/II trials and 1 phase II trial have evaluated the safety and efficacy of oral ...
J. Tanner Ringley, Donald C. Moore, Jolly Patel   +2 more
core   +1 more source

The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

Genes and Diseases
Chronic myeloid leukemia (CML) is a common adult leukemia. Both the acute phase of the disease and the adverse effects of anti-cancer treatments can lead to a poor prognosis.
Fangyi Yao, Fangmin Zhong, Junyao Jiang, Ying Cheng, Shuai Xu, Jing Liu, Jin Lin, Jing Zhang, Shuqi Li, Meiyong Li, Yanmei Xu, Bo Huang, Xiaozhong Wang   +12 more
doaj   +1 more source

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations

Cancer Management and Research, 2022
Maximillian S Wu, Hanan Goldberg Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USACorrespondence: Hanan Goldberg, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, 13520, USA, Tel +1-315-271-4173, Email gohanan@
Wu MS, Goldberg H
doaj  

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

Cancer Management and Research, 2019
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu ZhangDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaAbstract: Poly (ADP-ribose) polymerase (PARP) inhibitors
Jiang X, Li W, Li X, Bai H, Zhang Z
doaj  

Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself [PDF]

Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplement the potencies of other agents, is a promising strategy in cancer treatment.
McCrudden CM, Hagan C, Hirst DG, Curtin NJ, Shaw C, O'Sullivan JM, Yuen HF, O'Rourke MG, Babur M, Nambirajan T, Williams KJ, Thomas HD, Robson T, Telfer BA, Keane P, O'Rourke D, Cherry KE   +16 more
core   +1 more source

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma

Journal of Experimental & Clinical Cancer Research
Background Serous endometrial cancer (SEC) is a genomically and morphologically distinct endometrial cancer (EC) subtype with a poor progression-free and overall survival. The development of novel therapies is needed to improve outcomes.
Xiaonan Hou, Valentina Zanfagnin, Conway Xu, Erik Jessen, Yuanhang Liu, Chen Wang, Yajue Huang, Shaun D. Fontaine, Daniel V. Santi, Gerardo Colon-Otero, Sarah E. Gill, Gretchen E. Glaser, Kristina A. Butler, Jamie N. Bakkum-Gamez, Sean C. Dowdy, Ann L. Oberg, Melissa C. Larson, Hunter J. Atkinson, Laura N. Duffield, Kevin L. Peterson, Scott H. Kaufmann, S. John Weroha   +21 more
doaj   +1 more source

Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effectsResearch in context

EBioMedicine
Summary: Background: Ovarian cancer is among the most lethal malignancies in women. The advent of PARP inhibitors (PARPi) has improved outcomes. However, treatment-related toxicity remains a critical challenge, impacting patient quality of life and ...
Deeksha Malhan, Janina Hesse, Nina Nelson, Kay Stankov, Jessica Nguyen, Ouda Aboumanify, Josefin Garmshausen, Gunther Rogmans, Bastian Czogalla, Jens Gerber, Martin Koch, Tomáš Kupec, Oliver Tomé, Ralf Witteler, Mustafa Deryal, Michael Eichbaum, Jalid Sehouli, Elena Ioana Braicu, Angela Relógio   +18 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source